Get started
Author

Samantha Di Donato

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
2020 · Chiara Cremolini, Carlotta Antoniotti, et al. · The Lancet Oncology · 352
PDF
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
2015 · C. Cremolini, F. Loupakis, et al. · Annals of Oncology · 196
PDF
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
2018 · E. Dell’Aquila, C. Cremolini, et al. · Annals of Oncology · 142
PDF
A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study
2019 · Fotios Loupakis, Rossana Intini, et al. · European Journal of Cancer · 68
PDF
5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer
2008 · Antonello Di Paolo, Monica Lencioni, et al. · Clinical Cancer Research · 62
PDF
Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper
2018 · Anna Rachelle Mislang, Samantha Di Donato, et al. · Journal of Geriatric Oncology · 61
PDF
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
2007 · Sergio Ricci, Giuseppe Boni, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 59
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
2019 · Marzia Del Re, Saverio Cinieri, et al. · The Pharmacogenomics Journal · 51
PDF
Results of the observational prospective RealFLOT study
2021 · Elisa Giommoni, Daniele Lavacchi, et al. · BMC Cancer · 50
PDF
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
2016 · Valentina Fanotto, Stefano Cordio, et al. · Gastric Cancer · 50
PDF
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
2023 · Sara Lonardi, Cosimo Rasola, et al. · Journal of Clinical Oncology · 45
PDF
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
2009 · E Vasile, G Masi, et al. · British Journal of Cancer · 38
PDF
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
2017 · Valentina Fanotto, Mario Uccello, et al. · The Oncologist · 36
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
2019 · Chiara Cremolini, Federica Marmorino, et al. · European Journal of Cancer · 34
Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools
2017 · Laura Biganzoli, Anna Rachelle Mislang, et al. · The Journals of Gerontology Series A · 34
First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.
2020 · Sara Lonardi, Marta Schirripa, et al. · Journal of Clinical Oncology · 33
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
2024 · Giovanni Randon, Sara Lonardi, et al. · The Lancet Oncology · 32
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
2017 · Chiara Cremolini, Marzia Del Re, et al. · Oncotarget · 32
PDF
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
2017 · on behalf of all the investigators of the Gruppo Oncologico del Nord Ovest, Chiara Cremolini, et al. · BMC Cancer · 32
PDF
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
2023 · Floriana Nappo, Lorenzo Fornaro, et al. · Journal of Cancer Research and Clinical Oncology · 29
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer
2019 · Filippo Pietrantonio, Giovanni Randon, et al. · Cancer Treatment Reviews · 29
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development
2023 · Roberto Moretto, Marco Maria Germani, et al. · British Journal of Cancer · 27
PDF
A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting
2021 · Samantha Di Donato, Alessia Vignoli, et al. · Cancers · 26
PDF
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
2023 · Filippo Pietrantonio, Francesca Bergamo, et al. · European Journal of Cancer · 24
PDF
Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO
2019 · Chiara Cremolini, Carlotta Antoniotti, et al. · SSRN Electronic Journal · 24
Works count: 105
Citation count: 2,164
H-index: 25
I10-index: 35
Year
Topic
Type